Barry D Quart

This inventor holds 19 USPTO granted patents and 13 published patent applications, plus 4 CIPO patents and 9 EPO patents. Top assignees: Ardea Biosciences, Inc, Napo Pharmaceuticals, Inc., Napo Pharmaceuaticals, Inc.. Active years: 2009-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Barry D Quart. Retrieved from https://idiyas.com/inventor/barry-d-quart

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 13)

% Patents Active = 84.2

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 2.4

ph-index = 8

Forward Citations = 165(Granted Patents)

Location History:

Las Vegas, NV (US) (2018)
Encinitas, CA (US) (2009 - 2020)

Company Filing History:

12 out of 63

Ardea Biosciences, Inc

patents

6 out of 15

Napo Pharmaceuticals, Inc.

patents

1 out of 1

Napo Pharmaceuaticals, Inc.

patent

Years Active: 2009-2020

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10570095 - 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same (2020-02-25),

2. 10183012 - Compounds and compositions and methods of use (2019-01-22),

3. 10047050 - 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same (2018-08-14),

4. 9987250 - Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer (2018-06-05),

5. 9980938 - Method for treatment of diarrhea-predominant irritable bowel syndrome (2018-05-29),

6. 9402827 - Treatment of gout (2016-08-02),

7. 9216179 - Treatment of gout and hyperuricemia (2015-12-22),

8. 9138450 - Method for treatment of constipation-predominant irritable bowel syndrome (2015-09-22),

9. 9095581 - Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof (2015-08-04),

10. 8852649 - Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer (2014-10-07),

11. 8846113 - Method for treatment of diarrhea-predominant irritable bowel syndrome (2014-09-30),

12. 8808742 - Compositions and methods for preparing and using same (2014-08-19),

13. 8648116 - Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same (2014-02-11),

14. 8546437 - Compounds and compositions and methods of use (2013-10-01),

15. 8357713 - Compounds and compositions and methods of use (2013-01-22),

Title: Barry D Quart: Innovator in Uric Acid Modulation

Introduction

Barry D Quart, based in Encinitas, CA, is a prolific inventor with a remarkable portfolio of 19 patents. His innovative work primarily focuses on compounds and methods that address medical needs related to blood or serum uric acid levels, providing significant contributions to the fields of pharmacology and medicine.

Latest Patents

Among his latest inventions is a patented compound known as 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid. This compound has proven useful in modulating blood or serum uric acid levels. The invention specifically describes its applications in the treatment and prevention of disorders associated with abnormal uric acid levels. Furthermore, it includes formulations and compositions comprising the said compound, highlighting their efficacy in reducing serum uric acid levels in humans.

Career Highlights

Barry D Quart has made notable strides in his professional journey, having worked with prominent organizations such as Ardea Biosciences, Inc. and Napo Pharmaceuticals, Inc. His career reflects a strong dedication to research and innovation, especially in developing therapeutic solutions to health issues related to uric acid.

Collaborations

Throughout his career, Barry has collaborated with esteemed colleagues, including Jean-Luc Girardet and Li-Tain Yeh. These partnerships have facilitated advancements in research and helped bring new therapies to the forefront of medical science.

Conclusion

Barry D Quart stands out as a significant figure in the realm of innovative medical inventions, particularly concerning uric acid management. His dedication to research, coupled with foundational collaborations and a robust patent portfolio, underscores his commitment to improving health outcomes through scientific advancement.

Profile summary based on public USPTO records.